Heartwood Wealth Advisors LLC Increases Stake in Johnson & Johnson (NYSE:JNJ)

Heartwood Wealth Advisors LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 13.4% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 11,069 shares of the company’s stock after purchasing an additional 1,307 shares during the period. Heartwood Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $1,836,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. MRP Capital Investments LLC boosted its stake in Johnson & Johnson by 4.1% during the 4th quarter. MRP Capital Investments LLC now owns 1,640 shares of the company’s stock worth $237,000 after purchasing an additional 65 shares during the period. Syverson Strege & Co boosted its stake in Johnson & Johnson by 4.9% during the 4th quarter. Syverson Strege & Co now owns 1,394 shares of the company’s stock worth $202,000 after purchasing an additional 65 shares during the period. Werba Rubin Papier Wealth Management boosted its stake in Johnson & Johnson by 3.3% during the 4th quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company’s stock worth $301,000 after purchasing an additional 66 shares during the period. Denali Advisors LLC boosted its stake in Johnson & Johnson by 1.3% during the 4th quarter. Denali Advisors LLC now owns 5,128 shares of the company’s stock worth $742,000 after purchasing an additional 67 shares during the period. Finally, Sage Mountain Advisors LLC boosted its stake in Johnson & Johnson by 0.5% during the 4th quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company’s stock worth $2,106,000 after purchasing an additional 67 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $150.77 on Friday. The company has a 50-day simple moving average of $154.11 and a 200-day simple moving average of $153.64. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $362.76 billion, a PE ratio of 16.77, a P/E/G ratio of 2.28 and a beta of 0.42. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The firm had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.45%. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio (DPR) is 57.84%.

Analyst Ratings Changes

A number of brokerages recently weighed in on JNJ. Benchmark upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research note on Thursday, April 24th. Sanford C. Bernstein restated a “market perform” rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Bank of America cut their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, April 10th. Finally, Leerink Partners downgraded shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Eleven investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.